Case todayHoldingThesis-Break EngineThe case · mixed · Oct 12, 2026Own AMIX if its nervous-system sensing/treatment technology produces clinical proof before cash runway and dilution overwhelm equity holders.5 conditions1 strengthening · 2 holding · 2 weakeningNext resultsNot scheduledNo date filed yet

AMIX at a glance

Short interest

History

55,505 shares

Since the last report
−5.9%
Days to cover
1.0 day
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 10 – Nov 16

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

AMIX price history

Latest price$1.37Today+$0.01 (+1.11%)
AMIX -54.33%S&P 500 -2.05%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Clinical and regulatory execution, not selling efficiency, is the value driver because Autonomix has not yet shown that its nervous-system device technology can become a commercial product.HoldingMateriality: High

    GAAP annual revenue was $0 in FY2023, FY2024, FY2025, and FY2026, confirming there is no commercial adoption yet. If clinical proof arrives, the company can begin to build a real business; if it does not, equity value remains a melting development option.

    Watch: A pivotal or feasibility study fails to show a clinically meaningful benefit or produces a safety signal.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue was $0 in FY2023, FY2024, FY2025, and FY2026, confirming there is no commercial adoption yet.

    Open source ↗
  • Financing access is an operating capability: the company must extend runway on acceptable terms long enough to fund clinical and regulatory milestones.WeakeningMateriality: High

    Cash was $7.004 million at FY2026 year-end. Even good science can be a bad stock if the next capital raise transfers most of the upside to new investors.

    Watch: The company cannot raise equity or strategic capital before a major clinical or regulatory milestone.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $7.004 million at FY2026 year-end.

    Open source ↗
  • Because there is no revenue base, rising spend creates value only if it directly buys clinical, regulatory, or intellectual-property milestones rather than unfocused overhead.WeakeningMateriality: Medium

    GAAP operating cash flow was negative $1.854 million in FY2023, negative $6.600 million in FY2024, negative $8.258 million in FY2025, and negative $12.282 million in FY2026. Capital discipline determines whether each dollar of dilution increases the probability of success or merely shortens runway.

    Watch: Clinical timelines slip while cash burn continues at the current or higher pace.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP operating cash flow was negative $1.854 million in FY2023, negative $6.600 million in FY2024, negative $8.258 million in FY2025.

    Open source ↗
  • Low balance-sheet claims preserve equity optionality, but that advantage disappears if the company funds development with senior debt, vendor arrears, or punitive convertibles.StrengtheningMateriality: Medium

    Liabilities were $1.705 million at FY2026 year-end, broadly stable versus $1.707 million at FY2025 year-end. For a pre-revenue issuer, who owns the claims on the asset can matter as much as whether the asset ultimately works.

    Watch: The company issues secured debt or convertible securities with senior claims on the technology.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Liabilities were $1.705 million at FY2026 year-end, broadly stable versus $1.707 million at FY2025 year-end.

    Open source ↗
  • Autonomix’s eventual pricing power depends on its nervous-system sensing/treatment technology proving meaningfully better than existing device or drug approaches, not merely being novel.HoldingMateriality: Medium

    The company describes itself as a development-stage medical device company advancing technologies for sensing and treating disorders of the nervous system. Differentiation is what would allow reimbursement, physician adoption, and durable economics; without it, commercialization could fail even after technical development.

    Watch: Incumbent neuromodulation, ablation, or diagnostic-device companies such as Medtronic, Boston Scientific, or Abbott demonstrate comparable outcomes with established platforms.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The company describes itself as a development-stage medical device company advancing technologies for sensing and treating disorders of the nervous.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Clinical and regulatory execution, not selling efficiency, is the value driver because Autonomix has not yet shown that its nervous-system device technology can become a commercial product. If clinical proof arrives, the company can begin to build a real business; if it does not, equity value remains a melting development option.

Financing access is an operating capability: the company must extend runway on acceptable terms long enough to fund clinical and regulatory milestones. Even good science can be a bad stock if the next capital raise transfers most of the upside to new investors.

Because there is no revenue base, rising spend creates value only if it directly buys clinical, regulatory, or intellectual-property milestones rather than unfocused overhead. Capital discipline determines whether each dollar of dilution increases the probability of success or merely shortens runway.

Low balance-sheet claims preserve equity optionality, but that advantage disappears if the company funds development with senior debt, vendor arrears, or punitive convertibles. For a pre-revenue issuer, who owns the claims on the asset can matter as much as whether the asset ultimately works.

Autonomix’s eventual pricing power depends on its nervous-system sensing/treatment technology proving meaningfully better than existing device or drug approaches, not merely being novel. Differentiation is what would allow reimbursement, physician adoption, and durable economics; without it, commercialization could fail even after technical development.

All standing thesis claims
Original report summary

its nervous-system sensing/treatment technology produces clinical proof before cash runway and dilution overwhelm equity holders.

Evidence assessed Oct 12, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Autonomix Medical

Where the evidence on Autonomix Medical disagrees: Mixed on the latest evidence (Oct 12, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.

Bull case: what the evidence supports

  • Clinical and regulatory execution, not selling efficiency, is the value driver because Autonomix has not yet shown that its nervous-system device technology can become a commercial product.

    sec.gov ↗

  • Low balance-sheet claims preserve equity optionality, but that advantage disappears if the company funds development with senior debt, vendor arrears, or punitive convertibles.

    sec.gov ↗

  • Autonomix’s eventual pricing power depends on its nervous-system sensing/treatment technology proving meaningfully better than existing device or drug approaches, not merely being novel.

    sec.gov ↗

Bear case: what the evidence questions

  • Financing access is an operating capability: the company must extend runway on acceptable terms long enough to fund clinical and regulatory milestones.

    sec.gov ↗

  • Because there is no revenue base, rising spend creates value only if it directly buys clinical, regulatory, or intellectual-property milestones rather than unfocused overhead.

    sec.gov ↗

Company research

Research on Autonomix Medical

Thesis-Break Engine

Thesis-break watch · Autonomix Medical

No break has crossed Autonomix Medical’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Director or principal officer change.

    Autonomix Medical filed an SEC 8-K on 2026-09-16: Director or principal officer change. It is a dated development that tests the current thesis.

  2. Mixed
    Entered a material definitive agreement.

    Autonomix Medical filed an SEC 8-K on 2026-08-26: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  3. Mixed
    Other material event.

    Autonomix Medical filed an SEC 8-K on 2026-07-28: Other material event. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A pivotal or feasibility study fails to show a clinically meaningful benefit or produces a safety signal.
  • The company cannot raise equity or strategic capital before a major clinical or regulatory milestone.
  • Clinical timelines slip while cash burn continues at the current or higher pace.
  • The company issues secured debt or convertible securities with senior claims on the technology.
  • Incumbent neuromodulation, ablation, or diagnostic-device companies such as Medtronic, Boston Scientific, or Abbott demonstrate comparable outcomes with established platforms.

AMIX news

Loading headlines…

Financial statements

AMIX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

AMIX: quick answers

What is AMIX's short interest?
As of October 30, 2026, 55,505 AMIX shares were sold short, down 5.9% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. AMIX short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.